rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

BioCardia, Inc.

BCDA · Nasdaq

Health CareBiotechnologyNot moving yet

BCDA stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 10.2% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−9 points in four weeks); Health Care: 28% (−6 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
18% -9 in 4 wk
Insider buys, 12 months
$337K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
20 (+3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

23 Apr – 22 Oct
18%29%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$885KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months34
Sale orders, 12 months0
Buyers · sellers2 · 0
WhoDidSharesTraded
Peter AltmanPresident and CEObought300at $0.9516 Oct 2026filed 20 Oct 2026
Peter AltmanPresident and CEObought200at $0.9515 Oct 2026filed 20 Oct 2026
Peter AltmanPresident and CEObought1,000at $1.0329 Sep 2026filed 30 Sep 2026
Peter AltmanPresident and CEObought1,900at $1.0523 Sep 2026filed 23 Sep 2026
Peter AltmanPresident and CEObought800at $1.093 Sep 2026filed 4 Sep 2026
Peter AltmanPresident and CEObought5,400at $0.9317 Aug 2026filed 18 Aug 2026
Peter AltmanPresident and CEObought1,900at $0.9213 Aug 2026filed 13 Aug 2026
Peter AltmanPresident and CEObought5,000at $0.7829 Jul 2026filed 29 Jul 2026
Peter AltmanPresident and CEObought500at $0.8317 Jul 2026filed 20 Jul 2026
Peter AltmanPresident and CEObought1,500at $0.8615 Jul 2026filed 15 Jul 2026
Peter AltmanPresident and CEObought2,800at $0.8814 Jul 2026filed 15 Jul 2026
Peter AltmanPresident and CEObought1,000at $0.9410 Jul 2026filed 10 Jul 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders20+3 on the quarter
New · exited7 · 4
Reported value$1.6M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
CITIGROUP INCnew · filed 3 Aug 2026397,594$493K+397,594
CM Management, LLCadded · filed 13 Aug 2026300,000$372K+170,000+130.8%
VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 2026124,591$154K00.0%
Pingora Partners LLCadded · filed 14 Aug 2026120,382$149K+84,643+236.8%
UBS Group AGnew · filed 13 Aug 202677,619$96K+77,619
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202666,664$83K-27,623−29.3%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 202666,270$82K00.0%
SUSQUEHANNA INTERNATIONAL GROUP, LLPreduced · filed 14 Aug 202638,809$48K-180.0%
BROWN ADVISORY INCunchanged · filed 14 Aug 202635,538$44K00.0%
COMMONWEALTH EQUITY SERVICES, LLCadded · filed 29 Jul 202623,383$29K+5,100+27.9%
30 Jun 2024 – 30 Jun 2026
81420Jun 24Dec 24Jun 25Dec 25Jun 26

Everyone who traded it

Peter Altman Company insiderPresident and CEO · last 16 Oct 2026144 · 1
Andrew Scott Blank Company insiderDirector · last 6 Jul 20264 · 0
Bill Facteau Company insiderDirector · last 6 Jul 20261 · 0
David McClung Company insiderChief Financial Officer · last 6 Jul 20268 · 0
Edward M. Gillis Company insiderSenior Vice President, Devices · last 6 Jul 20260 · 1
Jay M. Moyes Company insiderDirector · last 6 Jul 20260 · 0
Jim L. Allen Company insiderDirector · last 6 Jul 20261 · 0
Marvin Slosman Company insiderDirector · last 6 Jul 20260 · 0
Simon H. Stertzer Company insiderDirector · last 6 Jul 202630 · 0
Richard M. Krasno Company insiderDirector · last 23 Apr 20251 · 0
Phillip Et Al Frost Company insider10% owner · last 19 Jan 202412 · 1
Krisztina M. Zsebo Company insiderDirector · last 10 Jun 20220 · 0

Same industry

IOVA Iovance BiotherapeuticsLeading+124%
MRNA ModernaLeading+118%
ENTX Entera BioLeading+51%
ABCL AbCellera BiologicsLeading+50%
HALO Halozyme TherapeuticsLeading+47%
XNCR XencorLeading+44%
XERS Xeris Biopharma HoldingsLeading+42%
CPIX Cumberland PharmaceuticalsLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2025 · to 24 Mar 20261.7%
Cash and equivalentsFY 2025 · to 31 Dec 2025$2.5M
Free cash flowFY 2025 · to 31 Dec 2025−$7.4M

Analyst forecasts

No analyst forecasts yet.